In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Spero closes $51.7mm Series C

08 Mar 2017

Executive Summary

Antibacterials developer Spero Therapeutics LLC raised $51.7mm in an oversubscribed Series C financing led by first-time backer GV (formerly Google Ventures), which was joined by other new investors RA Capital Management and Rock Springs Capital and returning shareholders Atlas Venture, SR One, MRL Ventures Fund, Lundbeckfonden Ventures, The Kraft Group, and Osage University Partners. The company will use the funds for ongoing development of its pipeline candidates aimed at drug-resistant bacterial infections including preclinical SPR994 and its clinical-stage Potentiator program.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By